- Home
- UTHR
as 11-03-2025 3:56pm EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 20.7B | IPO Year: | 1999 |
| Target Price: | $472.94 | AVG Volume (30 days): | 629.5K |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 26.38 | EPS Growth: | 16.08 |
| 52 Week Low/High: | $266.98 - $479.50 | Next Earning Date: | 10-29-2025 |
| Revenue: | $3,128,400,000 | Revenue Growth: | 13.50% |
| Revenue Growth (this year): | 13.82% | Revenue Growth (next year): | 5.71% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Oct 30 '25 | Sell | $450.58 | 11,000 | $4,953,760.38 | 36,781 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 28 '25 | Sell | $415.50 | 4,000 | $1,661,555.06 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 27 '25 | Sell | $415.55 | 4,000 | $1,662,173.15 | 130 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Oct 27 '25 | Sell | $417.50 | 22,500 | $9,393,671.25 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 24 '25 | Sell | $424.86 | 4,000 | $1,696,259.41 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 23 '25 | Sell | $422.79 | 4,000 | $1,688,729.50 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 22 '25 | Sell | $421.90 | 4,000 | $1,688,607.13 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 21 '25 | Sell | $428.53 | 4,000 | $1,711,042.64 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 20 '25 | Sell | $425.96 | 4,000 | $1,698,349.58 | 130 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Oct 20 '25 | Sell | $427.41 | 22,500 | $9,616,702.50 | 130 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Is United Therapeutics' Stock Surge Justified After Pulmonary Hypertension Advances?
Simply Wall St.
4 days ago
United Therapeutics (UTHR): Earnings Growth Slows, Reinforcing Cautious Market Narratives Despite High Margins
MT Newswires
4 days ago
United Therapeutics Insider Sold Shares Worth $4,953,760, According to a Recent SEC Filing
GuruFocus.com
4 days ago
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ...
Zacks
5 days ago
MKKGY vs. UTHR: Which Stock Is the Better Value Option?
Motley Fool
5 days ago
United Therapeutics (UTHR) Earnings Transcript
StockStory
5 days ago
UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook
Investor's Business Daily
5 days ago
United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.